866-997-4948(US-Canada Toll Free)

Periodontitis - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Jun 2013

Category :

Dental Devices

No. of Pages : 40 Pages


Global Markets Directs, Periodontitis - Pipeline Review, H1 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Periodontitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Periodontitis. 

Periodontitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Periodontitis.
  • A review of the Periodontitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Periodontitis pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Periodontitis.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Periodontitis pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Periodontitis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Periodontitis 7
Periodontitis Therapeutics under Development by Companies 9
Periodontitis Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Discovery and Pre-Clinical Stage Products 12
Comparative Analysis 12
Periodontitis Therapeutics Products under Development by Companies 13
Periodontitis Therapeutics Products under Investigation by Universities/Institutes 14
Companies Involved in Periodontitis Therapeutics Development 15
Aphios Corporation 15
Kaken Pharmaceutical Co.,Ltd. 16
CSL Limited 17
NeoStem, Inc. 18
Onepharm Research and Development GmbH 19
Canopus BioPharma Incorporated 20
Ensoltek Co., Ltd. 21
Periodontitis Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
POD CRC-OHS - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
trafermin - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Asterias - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Stem cell Therapy For Osteoporosis And Bone Regeneration - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
C5a Receptor Antagonist - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Sharon-3000 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
OPM-3023 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Periodontitis Therapeutics Drug Profile Updates 35
Periodontitis Therapeutics - Dormant Products 36
Periodontitis Product Development Milestones 37
Featured News & Press Releases 37
Nov 20, 2012: NeoStem Receives Notification Of $1.2m NIH Grant Award For First Clinical Study Of VSEL Technology In Humans 37
Mar 30, 2012: Kaken Pharma To Initiate Additional Phase III Trial For KCB-1D 37
Oct 21, 2004: Kaken Pharmaceutical Announces Results Of Early Phase II Clinical Trial On KCB-1D 38

Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Table


Number of Products Under Development for Periodontitis, H1 2013 7
Products under Development for Periodontitis Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 14
Aphios Corporation, H1 2013 15
Kaken Pharmaceutical Co.,Ltd., H1 2013 16
CSL Limited, H1 2013 17
NeoStem, Inc., H1 2013 18
Onepharm Research and Development GmbH, H1 2013 19
Canopus BioPharma Incorporated, H1 2013 20
Ensoltek Co., Ltd., H1 2013 21
Assessment by Monotherapy Products, H1 2013 22
Assessment by Stage and Route of Administration, H1 2013 24
Assessment by Stage and Molecule Type, H1 2013 26
Periodontitis Therapeutics Drug Profile Updates 35
Periodontitis Therapeutics Dormant Products 36

List of Chart


Number of Products under Development for Periodontitis, H1 2013 7
Products under Development for Periodontitis Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Discovery and Pre-Clinical Stage Products, H1 2013 12
Assessment by Monotherapy Products, H1 2013 22
Assessment by Route of Administration, H1 2013 23
Assessment by Stage and Route of Administration, H1 2013 24
Assessment by Molecule Type, H1 2013 25
Assessment by Stage and Molecule Type, H1 2013 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *